Common use of Development and Commercialization Program Clause in Contracts

Development and Commercialization Program. 2.1 Commencing on the Effective Date, the parties shall collaborate in the development and commercialization of the Licensed Product in the Licensed Field. The program of activities to be conducted by each of Corixa and Medicis during the term of the Agreement as set forth on Exhibit D to be attached hereto prior to the Effective Date (the “Development and Commercialization Program”), which may be reviewed no less often than on an annual basis by the Development Steering Committee or the Commercialization Steering Committee, as applicable, and, if necessary and appropriate, amended by the written agreement of the parties after recommendation by the Development Steering Committee or the Commercialization Steering Committee, as appropriate, effective upon the next anniversary of the Effective Date. The Development and Commercialization Program shall include a development plan setting forth the activities and timelines currently contemplated by the parties to be performed in developing the Licensed Products, as well as a description of each party’s responsibilities in connection with the development and commercialization of the Licensed Products. The timelines included in the Development and Commercialization Program may be modified from time to time by the Development Steering Committee or the Commercialization Steering Committee, as appropriate. The parties agree that the end goal of the Development and Commercialization Program shall be the expeditious clinical development and regulatory approval of the Licensed Products and optimization for successful commercialization as necessary for the import, manufacture, marketing and/or sale thereof in the Territory in the Licensed Field. No material deviation in the subject matter, scope and timeline of such Development and Commercialization Program shall be made without the written agreement of the parties. 2.2 Subject to the terms and conditions of this Agreement, the parties acknowledge and agree that nothing in this Agreement shall restrict Corixa’s ability to conduct clinical trials of any nature related to the Licensed Products using good clinical practice either inside or outside of the Licensed Field at Corixa’s or any of its Third Party Partners’ own cost and expense, provided that [***]. Notwithstanding the foregoing, Corixa shall provide Medicis access to and permit use of clinical data and regulatory filings controlled by Corixa related to the Licensed Products in the Licensed Field, and shall also use reasonable best efforts to [***].

Development and Commercialization Program. 2.1 Commencing on the Effective Date, the parties shall collaborate in the development and commercialization of the Licensed Product in the Licensed Field. The program of activities to be conducted by each of Corixa and Medicis ZKC during the term of the Agreement as is set forth on Exhibit D to be attached hereto prior to the Effective Date C (the “"Development and Commercialization Program”"), which may shall be reviewed no less often than amended on an annual basis by the Development Steering Committee or the Commercialization Steering Committee, as applicable, and, if necessary and appropriate, amended by the written mutual agreement of the parties after recommendation by the Development Steering Committee or the Commercialization Steering Committee, as appropriateparties, effective upon the next each anniversary ---------- * Confidential Treatment Requested of the Effective Date. The Development and Commercialization Program shall include a development plan setting forth the activities and timelines currently contemplated by the parties to be performed in developing the Licensed ProductsProduct, as well as a description of each party’s 's responsibilities in connection with the development and commercialization of the Licensed ProductsProduct. The Anything herein to the contrary notwithstanding, the timelines included in the Development development plan are [*] for the development of Licensed Product and Commercialization Program may be modified from time to time by the Development Steering Committee or the Commercialization Steering Committee, as appropriate. The parties agree that the end goal of the Development and Commercialization Program shall be the expeditious clinical development and regulatory approval of the Licensed Products and optimization for successful commercialization Product as necessary for the import, manufacture, marketing and/or sale thereof in the Territory in the Licensed Field. No material deviation in the subject matter, matter and scope and timeline of such Development and Commercialization Program shall be made without the mutual written agreement of the both parties. 2.2 Subject On the Effective Date, ZKC agrees to diligently undertake, [*] as determined by the Development Steering Committee or Commercialization Steering Committee, as applicable. ZKC shall have the right, subject to the terms and conditions of this Agreement, the including, without limitation, Section 3 hereof, to [*]. 2.3 The parties acknowledge and agree that nothing in this Agreement shall restrict Corixa’s ability to conduct clinical trials of in any nature related to the Licensed Products using good clinical practice either inside or outside of the Licensed Field at Corixa’s or any of its Third Party Partners’ own cost and expense, provided that manner [**], provided, however, Corixa shall not during the term of this Agreement [*]. Notwithstanding the foregoing, Corixa shall provide Medicis ZKC access to and permit use of clinical data and regulatory filings controlled by Corixa related to the Licensed Products in the Licensed Field[*], and shall also use reasonable best good faith efforts to cause any [*]. 2.4 The parties acknowledge and agree that nothing in this Agreement shall restrict in any manner [*], provided, however, ZKC shall not during the term of this Agreement [*]. Notwithstanding the foregoing, ZKC shall provide Corixa access to [**], and shall also use good faith efforts to cause any [*].

Development and Commercialization Program. 2.1 Commencing on the Effective Date, the parties shall collaborate in the development and commercialization of the Licensed Product in the Licensed Field. The program of activities to be conducted by each of Corixa and Medicis during the term of the Agreement as set forth on Exhibit D to be attached hereto prior to the Effective Date (the “"Development and Commercialization Program”"), which may be reviewed no less often than on an annual basis by the Development Steering Committee or the Commercialization Steering Committee, as applicable, and, if necessary and appropriate, amended by the written agreement of the parties after recommendation by the Development Steering Committee or the Commercialization Steering Committee, as appropriate, effective upon the next anniversary of the Effective Date. The Development and Commercialization Program shall include a development plan setting forth the activities and timelines currently contemplated by the parties to be performed in developing the Licensed Products, as well as a description of each party’s 's responsibilities in connection with the development and commercialization of the Licensed Products. The timelines included in the Development and Commercialization Program may be modified from time to time by the Development Steering Committee or the Commercialization Steering Committee, as appropriate. The parties agree that the end goal of the Development and Commercialization Program shall be the expeditious clinical development and regulatory approval of the Licensed Products and optimization for successful commercialization as necessary for the import, manufacture, marketing and/or sale thereof in the Territory in the Licensed Field. No material deviation in the subject matter, scope and timeline of such Development and Commercialization Program shall be made without the written agreement of the parties. 2.2 Subject to the terms and conditions of this Agreement, the parties acknowledge and agree that nothing in this Agreement shall restrict Corixa’s 's ability to conduct clinical trials of any nature related to the Licensed Products using good clinical practice either inside or outside of the Licensed Field at Corixa’s 's or any of its Third Party Partners’ ' own cost and expense, provided that [***]. Notwithstanding the foregoing, Corixa shall provide Medicis access to and permit use of clinical data and regulatory filings controlled by Corixa related to the Licensed Products in the Licensed Field, and shall also use reasonable best efforts to [*]. ------------------------------------ [**].] Confidential Treatment Requested